Cytotoxic drugs suppress many forms of immune and inflammatory response in animals (Gabrielsen and Good, 1967) . It has been argued that their immunosuppressive properties justify the use of these drugs in the treatment of putative autoimmune diseases in man. As a result they have been used to treat chronic inflammatory diseases including rheumatoid arthritis (Mason, Currey, Barnes, Dunne, Hazleman, and Strickland, 1969) . It is pertinent to ask, however, whether cytotoxic drugs do indeed suppress the immune response of patients with rheumatoid arthritis and to determine whether any such immunosuppression can be correlated with clinical improvement.
Material and methods

PATIENTS AND CONTROLS
All patients at Taplow who received cytotoxic drugs for the treatment of rheumatoid arthritis or juvenile rheumatoid arthritis (Still's disease) during the period March, 1966, to January, 1969, were studied. The clinical features of these twenty patients (Group A) are given in Table I (opposite).
One of these patients (Case 6) had some of the clinical features of disseminated lupus erythematosus. Because treatment with cytotoxic drugs was reserved for patients with complications, including amyloidosis, who had failed to respond to other drugs, this group consists of a small number of selected persons with severe disease.
The diagnosis of amyloid disease was confirmed by rectal biopsy.
A second group of 39 patients with severe rheumatoid arthritis or Still's disease was also studied (Group B). Their clinical features are summarized in Table II . Since their disease did not justify the use of cytotoxic drugs by our criteria, patients in this group had fewer disease complications than those in Group A. All in both groups had previously been treated with a combination of salicylates, phenylbutazone, chloroquine, Myocrisin, and steroids. The majority were receiving prednisone at the 
Rheumatoid 33 59 5(8 0-2-3 (1-4) 21 9 3 arthritis 100 0)
Still's 6 62-5(34*0-2-2 (1-3) 0 0 6 disease 84-0) time of study but none was receiving a dose greater than 11 mg. daily. Twenty healthy subjects, mainly hospital staff, served as controls (Group C).
The age and sex distribution of the three groups was comparable.
THERAPEUTIC VALUE OF CYTOTOXIC DRUGS
This report is concerned primarily with the immunological responses of patients treated with cytotoxic drugs and is not an account of the therapeutic trial of these drugs currently in progress (Zutshi, Ansell, and Bywaters, unpublished) . Thus only the principal change in disease activity associated with cytotoxic drug therapy are given in Table I .
Functional activity was assessed using five grades of activity (Empire Rheumatism Council, 1960) . Haematological and biochemical determinations were performed by standard methods; absolute lymphocyte counts were determined using a combination of Coulter counting and May-Grunwald Giemsa stained films. Latex tests were carried out on the sera of patients in Group A by the method of Valkenburg (1963) and on the sera of patients in Group B by an adaptation (Bywaters and Scott, 1960) of the method of Singer and Plotz (1956) .
Failure of cytotoxic drugs to suppress immune responses 221 Alternate patients were immunized either with polyvalent influenza vaccine, "Flugen" (Antigen 1), or with tetanus toxoid (Antigen 2). The first antigen was given before treatment with cytotoxic drugs and the second was injected 3 weeks after treatment had been started, when the blood lymphocyte count had fallen. Only a single injection of "Flugen" was given, but the first injection of tetanus toxoid was followed by a second injection 6 to 8 weeks later and a third after 6 months. Patients who had previously been immunized with tetanus toxoid received a single "booster" injection. Patients receiving cytotoxic drug therapy for longer than 10 weeks were immunized with a third antigen, brucella vaccine (Antigen 3).
The agents used to transform lymphocytes in vitro were of two kinds: those which the patients might have encountered naturally or against which they had previously been immunized, and those used in active immunization in this study.
No attempt was made to distinguish between primary and secondary antibody responses, as a variable degree of natural immunity almost certainly existed to these antigens, which were chosen for ethical reasons. Accordingly a rise in antibody titre after immunization was the only factor analysed. (Table I) .
IMMUNOLOGICAL METHODS
Lymphocyte transformation tests Lymphocytes from 20 ml. heparinized venous blood were cultured in Parker 199 medium and antigens were added on the first day of culture. Tritiated thymidine (H3 thymidine) was added on the 4th and 5th days of culture, and cells were harvested on the 6th day, except for cultures stimulated with phytohaemagglutinin (PHA) and purified protein derivative (PPD) which were harvested after 3 days and 5 days respectively. Nucleic acids were extracted and the amount of Hs thymidine incorporation was measured by liquid scintillation counting. Autoradiographs were prepared with Kodak AR 10 stripping film and were exposed for 7 days. Full details of these procedures have been given elsewhere (Vischer, 1966; . Whenever possible 2-0 x 106 mononuclear cells in 5 ml. were used in duplicate cultures, but in patients with profound lymphopenia it was often necessary to use 1 0 x 106 per culture in half the usual volume of medium. A positive response to an antigen or to PHA has been defined as a culture in which the incorporation of H3 thymidine, measured by liquid scintillation counting and autoradiography, was two or more times greater than H3 thymidine incorporation in cultures of mononuclear cells from the same patient to which antigen or PHA had not been added.
Several preliminary experiments were undertaken to define the most suitable culture conditions for this study, as it was apparent that lymphocyte yields from patients receiving cytotoxic drugs would be small. Filtration of blood lymphocytes through glass bead columns, to obtain cell suspensions free from granulocytes and consisting of 80 per cent. or more of lymphocytes, did not significantly affect the response to PHA. Similarly, this response was not materially altered by washing the lymphocytes and re-suspending them in autologous serum or foetal calf serum. Accordingly all cultures were subsequently set up in autologous plasma made up to 20 per cent. of the final volume with foetal bovine serum when necessary. There was initial concern that circulating cytotoxic drugs might suppress the ability of cultured lymphocytes to transform as a result of a direct action in vitro. However, the fact that the procedures described above did not influence the transforming capacity of lymphocytes obtained from patients who were receiving cytotoxic drugs at the time of culture justified the decision to set up cultures in autologous plasma.
The amount of PHA or antigen required to give the maximum degree of stimulation was established in a series of experiments in which the concentration per culture was varied from 1/10th to 10 times the concentration given in Skin reactions Skin tests were performed with 0-1 ml. of a 1: 1,000 solution of PPD and with 0-1 ml. of a streptokinasestreptodomase solution containing 10 units of streptokinase. The areas of erythema and induration were recorded at 24 and 48 hours after injection, using circles of standard diameter (Bencard). The results given are the maximum extent of erythema.
Circulating antibody (a) Influenza vaccine Each dose of 'Flugen' influenza vaccine contained a total of 15,000 haemagglutinating units of approximately equal amounts of the A and B strains of influenza virus prevalent during the years 1959-66. Children under the age of 12 years were given half the adult dose. Antibody titres were estimated by the haemagglutination-inhibition method using the A2/England/1961 and the B/England/1969 influenza strains as antigens. Details of this method have been previously described (Heath, Tyrrell, and Peto, 1962) . (b) Tetanus toxoid 0 5 ml. tetanus toxoid (Glaxo) was given. Antitoxin responses were measured by in vivo titration, using the mouse subcutaneous method. (c) Brucella vaccine Each dose of brucella vaccine contained 200 x 106 organisms in 0 1 ml. (Parke Davis, Detroit). Antibody titres were determined using an agglutination technique (Bailey and Scott, 1962) with Brucella abortus 0 suspension (Burroughs Wellcome) as antigen.
Serum immunoglobulin levels Serum levels of IgA, IgG, and IgM were determined by a radial immunodiffusion method (Fahey and McKelvey, 1965) group.bmj.com on May 29, 2017 -Published by http://ard.bmj.com/ Downloaded from drugs, responded poorly to PHA compared with those from patients in Group B. This was a consistent finding in repeated cultures and emphasizes that the patients in this group were highly selected. Nevertheless, the blood lymphocyte counts were initially within the normal range (Fig. 1) . During the course of treatment with cytotoxic drugs, the ability of the lymphocytes from these patients to respond to PHA improved and the lymphocytes from three patients which were initially totally unresponsive to PHA recovered the ability to respond to this stimulus. The PHA response of patients from Group A after treatment was comparable to that observed in patients with rheumatoid arthritis (Group B) and in normal controls (Group C), although the blood lymphocyte count had fallen to low levels at this time (Fig. 1) . The increased response to PHA in patients in Group A observed after treatment is highly significant (t = 2 -56; P = < 001).
(b) Response to naturally encountered antigens PPD Although ten patients from Group A had given a positive skin test to PPD in the year preceding treatment with cytotoxic drugs, the lymphocytes of only four of these patients were transformed by PPD in vitro (Fig. 2) Streptokinase andendotoxin The number of patients in Group A in whom transformation could be induced by streptokinase increased from four before treatment to twelve during treatment, a proportion comparable to that obtained in subjects in Groups B and C. A consistent response was obtained in serial cultures from individual patients (Fig. 2) Horizontal.-----= lower limit of significant response cytes from seven of ten patients immunized during the course of treatment produced a positive response (Fig. 3, above) . Similarly, the lymphocytes from six to eight patients immunized with tetanus toxoid whilst receiving cytotoxic drugs responded in vitro to this antigen, while only four of ten patients immunized before treatment showed a positive response. These findings show clearly that cytotoxic drugs failed to suppress lymphocyte transformation in vitro provoked by antigens administered during treatment. There is even a suggestion that this form of response was enhanced by administration of cytotoxic drugs, not only in comparison with the findings in Group A patients before treatment, but also in comparison with findings in subjects in Groups B and C. However, insufficient patients were tested for this possibility to be statistically verified.
Only a limited number of Group A patients were immunized with brucella antigen during the course of treatment with cytotoxic drugs. This antigen induced lymphocyte transformation as readily in these patients as in members of Group B.
CORRELATION BETWEEN RESULTS OBTAINED WITH SCINTILLATION COUNTING AND AUTORADIOGRAPHY
The results of lymphocyte stimulation tests presented above are those obtained by H3 thymidine incorporation measured by scintillation counting. In this (Fig. 4, opposite (Table V) . In five patients a rise in immunoglobulin level followed the cessation of treatment with cytotoxic drugs, suggesting a direct effect of -these drugs on immunoglobulin synthesis. In three patients a fall in the titre of rheumatoid factor occurred during treatment with cytotoxic drugs.
CORRELATION BETWEEN IMMUNOLOGICAL AND CLINICAL FINDINGS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CYTOTOXIC DRUGS
The clinical condition of most patients did not change sufficiently for any clear conclusions to be reached. Nevertheless falls in erythrocyte sedimentation rate, titres of rheumatoid factor, and immunoglobulin levels were observed during treatment with cytotoxic drugs at a time when there was no evidence of immunosuppression (Tables I and V) . These features are illustrated by the response to treatment of Case 2 (Fig. 5, overleaf) .
Discussion
Several reports have claimed that cytotoxic drugs benefited patients with rheumatoid arthritis and other chronic inflammatory diseases (Galens, Bull, and Bartholomew, 1964; Lorenzen and Videbaek, 1965; Corley, Lessner, and Larsen, 1966; Renier, Deshayes, Besson, Barazer, Delahaye, and Bregeon, 1967; Kahn, Bedoiseau, and de Seze, 1967; Fosdick, 'Parsons, and Hill, 1968) , although these reports have been criticized on the grounds that acceptable controlled trials were not undertaken (Christian, 1967; O'Brien, 1968) . Many of the therapeutic issues will undoubtedly be clarified by the studies of Mason and others (1969) . The rationale for the use of cytotoxic drugs in treatment of 'autoimmune' diseases rests on the assumption that they suppress the presumed immunological causes of these disorders. Although cytotoxic drugs are immunosuppressive in some animals (Borel and Schwartz, 1964) , recent reviews (Gabrielsen and Good, 1967; Schwartz, 1967) have stressed that the degree of immunosuppression produced by these drugs is markedly influenced by the nature, quantity, and timing of the immunization procedure and by the species of the recipient. It is also clear that cytotoxic drugs owe their immunosuppressive effects in animals to their ability to interfere with the proliferation of lymphoid cells at some but not all stages of the immune response (Berenbaum, 1969) , and that the secondary antibody response is relatively resistant to these drugs (Butler and Coons, 1964) . In animal models of autoimmune disease, cytotoxic drugs have been given during the induction process with good effect (Hoyer, Good, and Condie, 1962) . In man the drugs have been used to treat established 'autoimmune' disease at a stage when the immunological processes involved must be considered analogous to those of the secondary antibody response and of established cellular immunity. Animal experiments suggest that these immunological processes are resistant to the immunosuppressive action of cytotoxic drugs. This view is supported by the findings of Page, Condie, and Good (1964) and Moens and Brocteur (1965) , who showed that established immune responses in patients with rheumatoid arthritis, systemic lupus erythematosus, and plasma cell hepatitis were (1967) showed that the primary antibody response to keyhole-limpet haemocyanin of twenty patients with autoimmune diseases was affected by treatment with azathioprine and amethopterin. Thirteen of these patients produced IgM antibody exclusively and the remainder did not respond at all to the antigen. The secondary antibody response of the majority of the patients was also affected, although their isoagglutinin titres were little impaired. It seems probable that treatment with cytotoxic drugs was partially responsible for the partial immunosuppression observed in these patients, but the underlying disease process may also have played some part.
The immunological responses tested in our study must all be regarded as secondary, since even in the absence of a history of previous immunization, naturally acquired immunity cannot be excluded. Some suppression of the production of circulating antibody was seen in both groups of patients with rheumatoid arthritis, but this was no more marked in patients receiving azathioprine or chlorambucil at the time of immunization than in patients with similar disease activity who were not receiving these drugs. Although the antibody response of patients with rheumatoid arthritis is not usually abnormal (Rhodes, Scott, Markham, and Monk-Jones, 1969) (M6ller, 1969) . There is good evidence that lymphocytes which respond by blast transformation can be classed as. long-lived antigen-sensitive cells (Miller and Mitchell, 1969; Davies, 1969) , different in origin and life-span from the antibody-forming lymphocytes which can be detected in the peripheral blood after immunization (Simons and Fitzgerald, 1969) . It seems likely, therefore, that antigen-sensitive lymphocytes in theblood and some antibody-forming cells escape inactivation by cytotoxic drugs despite the profound fall in the circulating lymphocyte count.
The enhancement of cellular transformation seen in our study may have been analogous to the enhancement of antibody production seen after administration of 6-mercaptopurine (Chanmougan and Schwartz, 1966) and low dose irradiation (Dixon and McConahey, 1963 (Salomon and Benveniste, 1969) .
Skin reactions were not suppressed by cytotoxic drugs, although increased reactions did not accompany the increase in lymphocyte transformation. A dissociation between these two forms of the immune response has also been noted by Leventhal, Waldorf, and Talal (1967) .
There can be no doubt that the cytotoxic drugs used in this study had profound biological effects, including lymphopenia, reduction in serum levels of immunoglobulins and rheumatoid factor, and, unfortunately, suppression of the red cell series and platelet precursors in five patients. Nevertheless, it is perhaps not surprising that chlorambucil and azathioprine failed to suppress lymphocyte transformation and the secondary antibody response, since it is known that long-lived lymphocytes and plasma cells in rat lymph nodes are resistant to the action of the antimetabolic drugs cyclophosphamide and 6-mercaptopurine (Miller and Cole, 1967) . It has also been shown previously that the toxicity of cytotoxic drugs is independent of their immunosuppressive effects (Berenbaum and Brown, 1964) . Hurd and Ziff (1968) have shown that 6-mercaptopurine suppresses blood 'mononuclear cells' which are probably bone-marrow-derived macrophage precursor cells and not circulating small lymphocytes. The importance of bone-marrow-derived macrophages in chronic inflammatory lesions has been clearly demonstrated (Spector and Willoughby, 1968; Lubaroff and Waksman, 1968) . The possibility that these are also the cells primarily affected in man by cytotoxic drugs is strengthened by our observation that the 'mononuclear cells' appearing in skin windows in patients receiving these drugs are reduced in number and atypical in morphology (Denman and Denman, unpublished observations (Mackaness, 1969) . The converse situation is seen in mice receiving antilymphocyte globulin (Denman, Denman, and Embling, 1968) , in which a normal blood lymphocyte count masks the depletion of long-lived small lymphocytes needed for antigen recognition. It could be argued that the patients in the present study were suffering from disease which was too advanced for successful treatment. This is particularly true for the patients with amyloidosis, whose poor prognosis is well recognized (Smith, Ansell, and Bywaters, 1968) . Thus the clinical observations in this study give no useful answer to the question lucidly posed by Swanson and Schwartz (1967) whether immunosuppression is a necessary, irrelevant, or undesirable accompaniment of treatment with cytotoxic drugs. The same questions could well be asked about the apparent ability of these drugs to restore the responsiveness of lymphocytes from our patients to in vitro stimulation. Further studies, continued for longer periods, will be needed to establish these points and it will be necessary to take into account the blood concentrations of the immunosuppressive drugs (Bach, Dardenne, and Fournier, 1969) .
Summary
The immunological responses of twenty patients with rheumatoid arthritis or Still's disease were studied before and during treatment with azathioprine or chlorambucil and were compared with those of 39 patients with the same diseases who were not receiving cytotoxic drugs and with twenty healthy controls. Patients were immunized with tetanus toxoid, influenza vaccine, and brucella antigen. Cytotoxic drugs failed to suppress skin reactivity and the production of circulating antibody. Lymphocyte transformation in vitro after stimulation with phytohaemagglutinin or antigens was also not suppressed and may even have been enhanced. Nevertheless, rheumatoid factor titres and serum immunoglobulin levels were reduced in many patients. It is concluded that cytotoxic drugs aie not demonstrably immunosuppressive in patients with rheumatoid arthritis, and that antigen-sensitive and antibody-producing lymphocytes escape inactivation despite the concomitant peripheral lymphopenia.
The authors would like to thank Prof. E. G. L. Bywaters for his interest and Mr. P. Fiske for his help with the preparation of autoradiographs. L'insucces des medicaments cytotoxiques pour la suppression des reactions immunitaires chez les malades atteints de polyarthrite rhumatolde Les reactions immunologiques de vingt malades atteints d'arthrite rhumatoide ou de la maladie de Still ont ete 6tudiees avant et pendant le traitement avec l'azathioprine ou la chlorambucile et ont et compar&es A celles de 39 malades atteints des memes maladies et qui ne recevaient pas des medicaments cytoxiques et a vingt temoins sains. Les malades avaient ete immunises avec la toxoide du tetanos, le vaccin contre l'influenza et l'antigene du brucella. Les medicaments cytotoxiques n'avaient pas reussi a supprimer la reactivit6 de la peau et la production de l'anticorps en circulation. La transformation lymphocytique in vitro apres stimulation par la phytohemagglutinine ou les antigenes n'a pas aussi e supprimee et a et6 meme, peut-etre, augmentee. Neanmoins, les titres du facteur rhumatoide et les taux des immunoglobulines 6nt ete reduits chez beaucoup de malades. II a ete conclu que les m6dicaments cytotoxiques n'ont pas 6te demontres comme 6tant immuno-r6pressifs chez les malades atteints d'arthrite rhumatolde, et que les lymphocytes sensibles A l'antigene et produisants des anticorps echappaient A l'inactivation malgre la lymphop6nie p6riph6rique concomitante.
Fracaso de las drogas citotoxicas en la supresi6n de las reacciones inmunes en pacientes con poliartritis reumatoide Las reacciones inmunol6ogicas de veinte pacientes con artritis reumatoide o enfermedad de Still fueron estudiadas antes del tratamiento y durante el tratamiento con azatioprina o clorambucil y fueron comparadas con las reacciones de 39 pacientes con las mismas enfermedades, pero que no estaban recibiendo drogas citot6xicas, y con veinte testigos sanos. Los pacientes fueron inmunizados con tetano toxoide, vacuna de influenza y antigeno de brucella. Las drogas citot6xicas no lograron suprimir la reactividad de la piel ni la producci6n de anticuerpos circulantes. La transformaci6n in vitro de linfocitos despues de estimulaci6n con PHA o antigenos no fue tampoco suprimida y hasta pudiera haber sido incrementada. No obstante, los titulos del factor reumatoide y los niveles de suero inmunoglobulinico fueron reducidos en muchos pacientes. Se Ilega a la conclusi6n de que las drogas citotoxicas no son evidentemente inmunosupresivas en pacientes con artritis reumatoide, y que los linfocitos sensibles al antigeno y productores de anticuerpos eluden la inactivaci6n, a pesar de la linfopenia perif6rica concomitante.
